Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis.
A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide.
10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, 10th Office of Disease Prevention and Control, Department of Disease Control, Ministry of Public Health, Thailand. attaponche@yahoo.com
Attapon
A
Cheepsattayakorn
Ruangrong
R
Cheepsattayakorn
D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy*; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D010330:Patents as Topic
D000995:Antitubercular Agents